Results 211 to 220 of about 574,104 (383)

NSP7 Molecular Degrader Attenuates Coronaviral Infection Through the β‐TrCP1/FBXO5 Axis

Advanced Science, EarlyView.
Host E3 ligase FBXO5 as a key regulator that promotes K48‐linked ubiquitination and proteasomal degradation of SARS‐CoV‐2 NSP7, thereby suppressing viral replication. NSP7 ubiquitination is co‐regulated by β‐TrCP1 and TAF1. Small molecule BC24877 disrupts β‐TrCP1‐mediated degradation of FBXO5, stabilizing FBXO5 and enhancing NSP7 clearance ...
Yao Tong, Travis B. Lear, Ferhan Tuncer, John J. Villandre, Áine N. Boudreau, Bo Lin, Irene Alfaras, Jason R. Kennerdell, Daniel P. Camarco, Mads B. Larsen, Yun Hua, Yanwen Chen, Meigin E. Chandler, Ricardo Pineda, Simon M. Barratt‐Boyes, John W. Evankovich, Toren Finkel, Yuan Liu, Bill B. Chen   +18 more
wiley   +1 more source

Immunogold localisation of ubiquitin‐protein conjugates in Sf9 insect cells [PDF]

, 1993
Péter Lőw, F J Doherty, Miklós Sass, János Kovács, R. John Mayer, Lajos László   +5 more
openalex   +1 more source

Function and regulation of cullin–RING ubiquitin ligases

Nature reviews. Molecular cell biology, 2005
M. Petroski, R. Deshaies
semanticscholar   +1 more source

Targeting GPX4 to Induce Ferroptosis Overcomes Chemoresistance Mediated by the PAX8‐AS1/GPX4 Axis in Intrahepatic Cholangiocarcinoma

Advanced Science, EarlyView.
PAX8‐AS1 drives chemoresistance in intrahepatic cholangiocarcinoma by activating NRF2‐mediated GPX4 transcription and stabilizing GPX4 mRNA via IGF2BP3. Targeting the PAX8‐AS1/GPX4 axis with a GPX4 inhibitor enhances the efficacy of gemcitabine and cisplatin in preclinical models, offering a promising strategy to overcome chemotherapy resistance in ...
Zhi‐Wen Chen, Ji‐Jun Shan, Mo Chen, Zong Wu, Yi‐Ming Zhao, Hong‐Xu Zhu, Xin Jin, Yi‐Xiu Wang, Yi‐Bin Wu, Zhen Xiang, Zhi‐Wen Ding, Zhen‐Hai Lin, Long‐Rong Wang, Lu Wang   +13 more
wiley   +1 more source

Ubiquitin-conjugating enzymes UBC4 and UBC5 mediate selective degradation of short-lived and abnormal proteins. [PDF]

, 1990
Wolfgang Seufert, Stefan Jentsch
openalex   +1 more source

Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer. [PDF]

Breast Cancer (Dove Med Press)
Zhao K, Zhang J, Yang Z, Wang R, Shi Y, Ji Y, Zhang S, Liu M.   +7 more
europepmc   +1 more source

Remodeling the Physicochemical and Pharmacokinetic Properties of PROTAC via Lipid Nanodisks for Cancer Therapy

Advanced Science, EarlyView.
To solve the challenge of PROTACs in clinical potential due to poor water solubility and membrane permeability, a nanodelivery system based on lipid nanodisks loaded with MZ1 prodrug (LND‐MZ1) to remodel the physicochemical and pharmacokinetic properties of PROTAC MZ1 is elaborately proposed.
Meichen Pan, Chunrong Yang, Zhongliang Fu, Yuchen Yang, Ying Zhuo, Hongwei Hou, Jinghong Li   +6 more
wiley   +1 more source

Assembly of the 26 S complex that degrades proteins ligated to ubiquitin is accompanied by the formation of ATPase activity.

, 1990
T Armon, D Ganoth, Avram Hershko
openalex   +1 more source

Targeting KRAS in Cancer Therapy: Beyond Inhibitors. [PDF]

MedComm (2020)
Chen C, Peng Z, Zhang L.
europepmc   +1 more source

Dynamic Cap‐Mediated Substrate Access and Potent Inhibitor Design of Monkeypox Virus I7L Protease

Advanced Science, EarlyView.
The first crystal structure of MPXV I7L protease, revealing its unique dimeric form is resolved. The structures and MD simulations uncovered a dynamic cap region that regulates substrate access to the active site. The structural basis of substrate recognition and the catalytic mechanism are elucidated, which led to the development of a FRET‐based assay
Haixia Su, Guoqing Wu, Muya Xiong, Yuhang Wang, Junyuan Cao, Mengyuan You, Yingchun Xiang, Tianqing Nie, Minjun Li, Gengfu Xiao, Leike Zhang, Qiang Shao, Yechun Xu   +12 more
wiley   +1 more source